MorphoSys is a profitable growth company, building a strong therapeutic antibody pipeline with more than 70 projects originating from its proprietary technologies. MorphoSys participates in successful product development by its partners through milestones and future royalty payments for marketed drugs and increasingly also develops drugs on its own account for an even greater potential upside.
